El-Mawardy Mohamed, Abdel-Wahab Mohamed, Richardt Gert
Heart Center, Segeberger Kliniken GmbH (Academic Teaching Hospital of the Universities of Kiel and Hamburg), Bad Segeberg, Germany.
Expert Rev Cardiovasc Ther. 2014 Aug;12(8):1005-24. doi: 10.1586/14779072.2014.929942. Epub 2014 Jul 12.
Transcatheter aortic valve implantation (TAVI) has become the preferred treatment option for patients with symptomatic severe aortic stenosis who are inoperable or at high risk for surgical aortic valve replacement. TAVI has shown a clear mortality benefit compared to conservative treatment in inoperable patients, and is at least non-inferior to surgical aortic valve replacement in high-risk operable patients. Through improvements in the field of imaging, refinement in valve technologies, increasing operator and team experience and continuous valuable research, TAVI has developed rapidly in the past years and is expected to further boost in the near future. In this review, we discuss the technical and procedural aspects of TAVI, the acute and late outcomes, and highlight the current expectations and potential future development of this rapidly evolving technology.
经导管主动脉瓣植入术（TAVI）已成为有症状的严重主动脉瓣狭窄且无法进行手术或手术主动脉瓣置换术风险高的患者的首选治疗方案。与保守治疗相比，TAVI在无法手术的患者中已显示出明显的死亡率获益，并且在高风险可手术患者中至少不劣于手术主动脉瓣置换术。通过成像领域的改进、瓣膜技术的完善、操作人员和团队经验的增加以及持续有价值的研究，TAVI在过去几年中迅速发展，预计在不久的将来还会进一步发展。在本综述中，我们讨论了TAVI的技术和操作方面、急性和晚期结果，并强调了这项快速发展技术的当前期望和潜在的未来发展。
